Sotyku (deucravacitinib) is a tyrosine kinase 2 (TYK2) inhibitor that is indicated for moderate-to-severe plaque psoriasis and psoriatic arthritis. Sotyku was first approved in September 2022 for moderate-to-severe plaque psoriasis in adults. Recently, in March 2026, it was also approved for adults with active psoriatic arthritis.
Read on to learn more about Sotyku, including its warnings and precautions, dosage and administration information, and more.
Medication Overview:
- Brand Name: Sotyku
- Generic Name: Deucravacitinib
- Treatment for: moderate-to-severe plaque psoriasis, psoriatic arthritis
- Manufacturer(s): Bristol Myers Squibb
- Initial FDA Approval: September 2022
| Indicated Condition | Indication | Age | FDA Approval |
|---|---|---|---|
| Moderate-to-Severe Plaque Psoriasis | Indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Not recommended for use in combination with other potent immunosuppressants. | Adults | September 2022 |
| Active Psoriatic Arthritis | Indicated for the treatment of active psoriatic arthritis in adults. | Adults | March 2026 |
Warnings and Precautions:
Hypersensitivity Reactions: Hypersensitivity reactions, such as angioedema, have been reported. Discontinue if a clinically significant hypersensitivity reaction occurs.
Infections: Sotyku may increase the risk of infection. Avoid use in patients with active or serious infection. If a serious infection develops, discontinue Sotyku until the infection resolves.
Tuberculosis: Evaluate for latent or active TB prior to initiating treatment with Sotyku.
Malignancy: Malignancies including lymphomas were observed in clinical trials with Sotyku. Consider the benefits and risks prior to initiating or continuing Sotyku in patients with a malignancy.
Rhabdomyolysis and Elevated CPK: Discontinue Sotyku if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.
Laboratory Abnormalities: Periodically evaluate serum triglycerides. Evaluate liver enzymes at baseline and during Sotyku treatment in patients with known or suspected liver disease.
Immunizations: Avoid use of Sotyku with live vaccines.
Potential Risks Related to JAK Inhibition: It is not known whether TYK2 inhibition may be associated with the observed or potential adverse reactions of JAK inhibition. Higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with a JAK inhibitor compared to those treated with TNF blockers in patients with rheumatoid arthritis (RA). Sotyktu is not approved for use in RA.
Dosage and Administration:
For recommended evaluation prior to Sotyktu initiation, see Full Prescribing Information.
Recommended dosage is 6 mg orally once daily, with or without food.
Contraindications:
History of hypersensitivity reaction to deucravacitinib or any of the excipients in Sotyktu.
Adverse Reactions:
Most common adverse reactions (≥1%) are: upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, and acne.
Please note: This article is current as of March 24, 2026. Consult our clinical guidelines library or drug information tool to ensure you always have the most up-to-date information.
Sign up for alerts to keep up with the latest clinical guidelines and guideline updates.